1925-LB: Sustained Reduction in Blood Glucose Levels Reflecting Diabetes Remission in People with Type 2 Diabetes Using a Digital Health Platform

Attainment of remission from type 2 diabetes (T2D) is increasingly perceived as a treatment goal. Improvement in glycemic control can be attained through lifestyle intervention, potentially resulting in diabetes remission. Dario Health, a digital therapeutic platform, may assist in promoting lifestyle changes and support patients trying to achieve remission. A retrospective data analysis was performed on users with T2D who have reported not using insulin and were active on Dario platform 6 months during 2018-2024, measured their BG in the first month and 3 measurements in the last month. Monthly average blood glucose (AvgBG) and percentage of high readings (180 mg/dL) versus baseline (first month) were evaluated Paired sample t-test was used for testing differences in AvgBG. A linear mixed-effects model was applied to evaluate the changes in AvgBG and high-readings percentage over time. Finally, a simple slope analysis was used for the interpretation of the interaction of AvgBG and high-readings percentage with lifestyle activities. A group of 7240 users was evaluated (Age 53.8 (SD ±24.6); 41% females). A ratio of 44% (3169/7240) reduced their last monthly AvgBG to 140 mg/dL (equivalent to estimated A1c of 6.5). A sustained AvgBG of 140 mg/dL for at least three consecutive months was observed in 70% (2223/3169) of the users reflecting diabetes remission. The AvgBG was reduced by 15% vs. baseline (P.001) in this group. In addition, users at high-risk with a baseline AvgBG ≥183 mg/dL demonstrated significant reductions in AvgBG and high-readings percentage in their last month moderated by the number of monthly lifestyle activities (logging carbs, meals and physical activities) as revealed by the model (B=-.00, P=.02 and B=-.00, P=.002 respectively). This study exhibits the potential role of digital health technology to change individuals' behaviors during management of T2D and support patients to achieve remission. Disclosure Y. Fundoiano-Hershcovitz: Employee; DarioHealth Corp. I. Breuer Asher: None. O. Manejwala: Employee; DarioHealth Corp. Stock/Shareholder; DarioHealth Corp.